Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.

Aliment Pharmacol Ther. 2013 Apr;37(8):810-8. doi: 10.1111/apt.12270. Epub 2013 Mar 4.

2.

Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.

Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.

Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30.

3.

Obesity does not affect treatment outcomes with proton pump inhibitors.

Sharma P, Vakil N, Monyak JT, Silberg DG.

J Clin Gastroenterol. 2013 Sep;47(8):672-7. doi: 10.1097/MCG.0b013e31827e46be.

PMID:
23442835
4.

Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.

Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN.

Aliment Pharmacol Ther. 2009 Apr 1;29(7):742-54. doi: 10.1111/j.1365-2036.2009.03954.x. Epub 2009 Feb 7.

5.

Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.

Croxtall JD, Scott LJ.

Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. Review.

PMID:
20687622
6.

Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D.

Aliment Pharmacol Ther. 2009 Apr 1;29(7):731-41. doi: 10.1111/j.1365-2036.2009.03933.x.

7.

Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.

Metz DC, Pilmer BL, Han C, Perez MC.

Am J Gastroenterol. 2011 Nov;106(11):1953-60. doi: 10.1038/ajg.2011.220. Epub 2011 Aug 16.

8.

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.

Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1261-72. doi: 10.1111/j.1365-2036.2009.04013.x. Epub 2009 Apr 8.

9.

Dexlansoprazole for the treatment of esophagitis and GERD.

Davies SL.

Drugs Today (Barc). 2010 Feb;46(2):75-80. doi: 10.1358/dot.2010.46.2.1437714.

PMID:
20393635
10.

Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.

Wu MS, Tan SC, Xiong T.

Aliment Pharmacol Ther. 2013 Jul;38(2):190-201. doi: 10.1111/apt.12349. Epub 2013 May 29.

11.

Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.

Abel C, Desilets AR, Willett K.

Ann Pharmacother. 2010 May;44(5):871-7. doi: 10.1345/aph.1M685. Epub 2010 Apr 6. Review.

PMID:
20371754
12.

Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.

Bytzer P, van Zanten SV, Mattsson H, Wernersson B.

Aliment Pharmacol Ther. 2012 Oct;36(7):635-43. doi: 10.1111/apt.12007. Epub 2012 Aug 1.

13.

Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN.

Aliment Pharmacol Ther. 2009 Nov 1;30(9):895-907. doi: 10.1111/j.1365-2036.2009.04119.x. Epub 2009 Aug 14.

14.

Dexlansoprazole MR: a review.

Hershcovici T, Jha LK, Fass R.

Ann Med. 2011 Aug;43(5):366-74. doi: 10.3109/07853890.2011.554429. Epub 2011 Mar 3. Review.

PMID:
21366513
15.

Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research Group.

J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 2011 Aug 24.

PMID:
21861141
16.

Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.

Sharma P, Johnson DA, Monyak JT, Illueca M.

Aliment Pharmacol Ther. 2011 Aug;34(4):487-93. doi: 10.1111/j.1365-2036.2011.04736.x. Epub 2011 Jun 20.

17.

Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.

Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC.

Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021. Epub 2011 Dec 7.

PMID:
22155561
18.

The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.

Nojkov B, Rubenstein JH, Adlis SA, Shaw MJ, Saad R, Rai J, Weinman B, Chey WD.

Aliment Pharmacol Ther. 2008 Mar 15;27(6):473-82. doi: 10.1111/j.1365-2036.2008.03596.x. Epub 2008 Jan 10.

19.

Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.

Emerson CR, Marzella N.

Clin Ther. 2010 Aug;32(9):1578-96. doi: 10.1016/j.clinthera.2010.08.008. Review.

PMID:
20974316
20.

Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.

Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research (ARS) Group.

J Gastroenterol Hepatol. 2012 May;27(5):899-906. doi: 10.1111/j.1440-1746.2011.06975.x.

PMID:
22098590

Supplemental Content

Support Center